Scarica l'app Stockscreener
10.93
0.27%
-0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$10.96
Aprire:
$10.92
Volume 24 ore:
919.78K
Relative Volume:
0.34
Capitalizzazione di mercato:
$1.24B
Reddito:
-
Utile/perdita netta:
$-242.30M
Rapporto P/E:
-4.4073
EPS:
-2.48
Flusso di cassa netto:
$-192.10M
1 W Prestazione:
-9.29%
1M Prestazione:
-0.46%
6M Prestazione:
+29.81%
1 anno Prestazione:
+27.39%
Intervallo 1D:
$10.72
$10.97
Intervallo di 1 settimana:
$10.38
$12.02
Portata 52W:
$3.72
$12.97
Cogent Biosciences Inc Stock (COGT) Company Profile
Nome
Cogent Biosciences Inc
Settore
Industria
Telefono
617-945-5576
Indirizzo
275 WYMAN STREET, WALTHAM
Confronta COGT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
10.93 | 1.53B | 0 | -242.30M | -192.10M | -2.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
638.90 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-11 | Downgrade | Needham | Buy → Hold |
| 2024-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Iniziato | Citigroup | Buy |
| 2023-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-12-08 | Iniziato | JP Morgan | Overweight |
| 2023-04-28 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-27 | Ripresa | H.C. Wainwright | Buy |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-06-28 | Iniziato | Guggenheim | Buy |
| 2021-10-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-06-09 | Ripresa | Jefferies | Buy |
| 2020-12-23 | Iniziato | Piper Sandler | Overweight |
| 2020-10-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Cogent Biosciences Inc Borsa (COGT) Ultime notizie
HC Wainwright Issues Pessimistic Forecast for Cogent Biosciences (NASDAQ:COGT) Stock Price - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
How Investors Are Reacting To Cogent Biosciences (COGT) Widening Losses in Q2 and First Half 2025 - simplywall.st
Wedbush Has Pessimistic Outlook of COGT FY2025 Earnings - MarketBeat
Q3 Earnings Estimate for COGT Issued By Leerink Partnrs - MarketBeat
JPMorgan Chase & Co. Increases Cogent Biosciences (NASDAQ:COGT) Price Target to $30.00 - MarketBeat
Q3 EPS Estimate for Cogent Biosciences Decreased by Analyst - MarketBeat
Cogent Biosciences shares fall 1.64% intraday after Cogent Communications misses Q2 net loss per share estimates. - AInvest
Cogent Biosciences Reports Positive Trial Results, Updates Financial Position - AInvest
Scotiabank Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $17 - 富途牛牛
COGT Stock Rating Maintained by HC Wainwright, Price Target Lowe - GuruFocus
Cogent Biosciences (COGT) Price Target Revised by Analyst - GuruFocus
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $18.70 Consensus Target Price from Brokerages - MarketBeat
Cogent Biosciences Reports Increased Losses Amidst Ongoing Development - TipRanks
Decoding Cogent Biosciences Inc (COGT): A Strategic SWOT Insight - GuruFocus
Promising Pipeline and Financial Stability Drive Buy Rating for Cogent Biosciences - TipRanks
Cogent Biosciences: KDJ Golden Cross and Bullish Marubozu Indicators Detected - AInvest
Cogent Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cogent Biosciences Reports Recent Business Highlights and Secon - GuruFocus
Cogent Biosciences' Q2 net loss widens as costs mount - TradingView
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results - GlobeNewswire
BRIEF-Cogent Biosciences Q2 Operating Expenses USD 75.581 Million - TradingView
Cogent's NonAdvSM Drug Trial Hits All Endpoints with 87% Response Rate, Two More Pivotal Results Coming - Stock Titan
Chart Analysts Warn of Resistance Near Cogent Biosciences Inc. PriceEntry Points For Growing Stocks Identified by Models - beatles.ru
What are analysts’ price targets for Cogent Biosciences Inc. in the next 12 monthsConsistently outstanding ROI - Jammu Links News
Should I hold or sell Cogent Biosciences Inc. stock in 2025Explosive returns - Jammu Links News
What drives Cogent Biosciences Inc. stock priceAchieve breakthrough gains with smart trades - Jammu Links News
Is it the right time to buy Cogent Biosciences Inc. stockTriple-digit returns - Jammu Links News
How strong is Cogent Biosciences Inc. company’s balance sheetGet daily updates on the hottest stocks - Jammu Links News
What is Cogent Biosciences Inc. company’s growth strategyGet real-time alerts on high-potential stocks - Jammu Links News
Y Intercept Hong Kong Ltd Sells 31,538 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
What makes Cogent Biosciences Inc. stock price move sharplyExplosive capital appreciation - Jammu Links News
What is the risk reward ratio of investing in Cogent Biosciences Inc. stockCapitalize on market trends with confidence - Jammu Links News
Cogent Biosciences (COGT) to Release Quarterly Earnings on Tuesday - MarketBeat
What institutional investors are buying Cogent Biosciences Inc. stockRetirement Planning Insights For 2025 - Jammu Links News
Published on: 2025-07-30 07:09:48 - metal.it
Key External Factors That Drive Cogent Biosciences Inc. Stock Price MovementsRisk Controlled Picks With Real Returns Outlined - metal.it
Cogent Biosciences Inc. Shows Early Signs of Technical StrengthSmart Investment Tips Gaining Popularity Among Analysts - metal.it
Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline - MSN
How Efficient Is Cogent Biosciences Inc. at Controlling Operating CostsIntraday Trend Analysis for Fast Gains Released - metal.it
Why Cogent Biosciences Inc. stock attracts strong analyst attentionAlpha Driven Watchlist With Alerts Published - metal.it
Published on: 2025-07-28 05:03:28 - jammulinksnews.com
What is the dividend policy of Cogent Biosciences Inc. stockMaximize returns with data-driven strategies - Jammu Links News
What are Cogent Biosciences Inc. company’s key revenue driversMaximize returns with smart investment plans - jammulinksnews.com
How volatile is Cogent Biosciences Inc. stock compared to the marketAchieve breakthrough gains with smart trades - Jammu Links News
When is Cogent Biosciences Inc. stock expected to show significant growthOutstanding capital appreciation - Jammu Links News
Cogent Biosciences Inc Azioni (COGT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.02%
3.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):